A Novel, wild-type sparing pan-EGFR Inhibitor (ZE77-0273) with Broad Activity Against Resistance Mutations in EGFR-Mutant NSCLC

Download Poster
Previous
Previous

Discovery of a novel, selective brain penetrant CDK2 inhibitor for targeted cancer therapy

Next
Next

A novel Selective BCL2 inhibitor with limited immune suppression and improved safety compared to venetoclax